Allurion Technologies (ALUR) shares surged more than 81% premarket Friday after the company said overnight that it plans to initiate a combination clinical study to improve muscle mass and overall body composition.
The clinical trial will combine the Allurion Program, a weight-loss platform, with GLP-1 agonists. The latter are primarily used to manage Type 2 diabetes and obesity.
The study aims to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can "lose significant weight while increasing muscle mass and improving overall body composition," Allurion Chief Executive Shantanu Gaur said late Thursday.
Price: 6.73, Change: +3.03, Percent Change: +81.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.